References
- Cobb P. W., Degen D. R., Clark G. M., Chen S. F., Kuhn J. G., Gross J. L., Kirshenbaum M. R., Sun J. H. H., Burris A., III, et al. Activity of DMP 840, a new bis-naph-thalimide, on primary human tumor colony-forming units. J. Natl. Cancer Inst. 1994; 86(19)1462–1465
- Houghton P. J., Cheshire P. J. J., Hallman C., III, Gross J. L., McRipley R. J., Sun J. H., Behrens C. H., Dexter D. L., Houghton J. A. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemother. Pharmacol. 1994; 33(4)265–272
- Kirshenbaum M. R., Chen S. F., Behrens C. H., Papp L. M., Stafford M. M., Sun J. H., Behrens D. L., Fredericks J. R., Polkus S. T., et al. (R, R)-2,2′-[1,2-ethane-diylbis[imino(1 -methyl -2, l-ethanediyl)]] -bis[5 -nitro -lH-benz[de]isoquinoline-l,3-(2H)-dione] dimethanesul-fonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Cancer Res. 1994; 54(8)2199–2206
- Houghton P. J., Cheshire P. J., Hallman J., Sun J. H., Behrens C. H., McRipley R. Evaluation of DMP 840, A novel anti-tumor agent in xenografts derived from adult and childhood malignancies. Proc. Am. Assoc. Cancer Res., 84th Meeting 1993; 368
- Mitchell R. B., Goss G., Guarino M., Keaton M., Hammond N., Finizio M., Gray J. Phase II trial of bisnafide in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 1996; 15(32nd Meeting)404
- Kline R. C., Melnychuk D., Schiano M., Reynolds K., Fung M. F. K., Finan M. A., Finizio M., Gray J. A phase II multicenter clinical trial of bisnafide in women with advanced refractory ovarian carcinoma. Proc. Am. Soc. Clin. Oncol. 1996; 15(32nd Meeting)293
- Maroun J., Guarino M., Goel R., Cripps C., Finizio M., Gray J. Phase II trial of bisnafide (B) in untreated patients with colorectal cancer (CRC). Proc. Am. Soc. Clin. Oncol. 1996; 15(32nd Meeting)219
- Avallone H. L. Drug substance manufacture and control. Pharm. Eng. 1989; 9(2)37–40; 57
- Harder S. W. The validation of cleaning procedures. Pharm. Technol. 1984; 8(5)29–34
- Mendenhall D. W. Cleaning validation. Drug Dev. Ind. Pharm. 1989; 15(13)2105–2114
- Jenkins K. M., Van denvielen A. J. Cleaning validation: An overall perspective. Pharm. Technol. 1994; 18(4)60–73
- Callan B. T. Cytotoxic drug containment. Pharm. Eng. 1994; 14(6)56–61
- Shea J. A., Shamrock W. F., Abboud C. A., Woodeshick R. W. L., Nguyen Q. S., Rubino J. T., Segretario J. Validation of cleaning procedures for highly potent drugs. I. Losoxantrone. Pharm. Dev. Technol. 1996; 1(1)69–75
- Sessink P. J. M., Anzion R. B. P. H. H., Van den Brock Bos R. P. Detection of contamination with antineo-plastic agents in a hospital pharmacy department. Pharm. Weekbl. (Sci.) 1992; 14(1)16–22
- Sessink P. J. M., Boer K. A., Scheefials A. P. H., Anzion R. B. M., Bos R. P. Occupational exposure to antineoplastic agents at several departments in a hospital. Int. Arch. Occup. Environ. Health 1992; 64(2)105–112
- Sessink P. J. M., Timmersmans J. L., Anzion R. B. M., Bos R. P. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil. J. Occup. Med. 1994; 36(1)79–83
- Altria K. D., Hadgett T. A. An evaluation of the use of capillary electrophoresis to monitor trace drug residues following the manufacture of pharmaceuticals. Chro-matographia 1995; 40(1/2)23–27
- Elrod L., Jr., Schmit J. L., Morley J. A. Determination of isoproterenol sulfate on surfaces using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. A 1996; 723: 235–241